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We have previously reported [Risatti, G.R., Borca, M.V., Kutish, G.F., Lu, Z., Holinka, L.G., French, R.A., Tulman, E.R., Rock, D.L. 2005a.
The E2 glycoprotein of classical swine fever virus is a virulence determinant in swine. J. Virol. 79, 3787–3796] that chimeric virus 319.1v
containing the E2 glycoprotein gene from Classical Swine Fever Virus (CSFV) vaccine strain CS with the genetic background of highly virulent
CSFV strain Brescia (BICv) was markedly attenuated in pigs. To identify the amino acids mediating 319.1v attenuation a series of chimeric
viruses containing CS E2 residues in the context of the Brescia strain were constructed. Chimera 357v, containing CS E2 residues 691 to 881 of
CSFV polyprotein was virulent, while chimera 358v, containing CS E2 residues 882 to 1064, differing in thirteen amino acids from BICv, was
attenuated in swine. Single or double substitutions of those amino acids in BICv E2 to CS E2 residues did not affect virulence. Groups of amino
acids were then substituted in BICv E2 to CS E2 residues. Mutant 32v, with six substitutions between residues 975 and 1059, and mutant 33v, with
six substitutions between 955 and 994, induced disease indistinguishable from BICv. Mutant 31v, with seven substitutions between residues 882
and 958, induced a delayed onset of lethal disease. Amino acids abrogating BICv virulence were then determined by progressively introducing six
CS residues into 31v. Mutant 39v, containing nine residue substitutions, was virulent. Mutant 40v, containing ten residue substitutions, induced
mild disease. Mutant 42v, containing twelve substitutions, and mutant 43v, with an amino acid composition identical to 358v, were attenuated in
swine indicating that all substitutions were necessary for attenuation of the highly virulent strain Brescia. Importantly, 358v protected swine from
challenge with virulent BICv at 3 and 28 days post-infection.
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Classical swine fever (CSF) is a highly contagious and often
fatal disease of swine, presenting as either an acute or chronic
infection characterized by fever and hemorrhage (van Oirschot,
1986). Disease outbreaks occur intermittently in Europe and
other parts of the world, resulting in significant economic losses.⁎ Corresponding author. Fax: +1 631 323 3006.
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doi:10.1016/j.virol.2007.02.025Classical swine fever virus (CSFV), the causative agent of the
disease, is a member of the Pestivirus genus of the Flaviviridae
family (Becher et al., 2003). CSFV is a small, enveloped virus
with a single-stranded 12.3 kb RNA genome of positive polarity
that contains a long open reading frame encoding a 3898-amino-
acid polyprotein. Cellular and viral proteases are used for co- and
post-translational processing of eleven to twelve final cleavage
products (Rice, 1996). Virus particles contain four structural
proteins: the core protein C and the envelope glycoproteins Erns,
E1 and E2 (Thiel et al., 1991). E1 and E2 are anchored to the
envelope by their carboxy termini, with Erns loosely associated
with the envelope. Erns and E2 are present as homodimers linked
by disulfide bridges on the surface of CSFV virions, whereas E2
372 G.R. Risatti et al. / Virology 364 (2007) 371–382is found dimerized with E1 (Thiel et al., 1991; Weiland et al.,
1990, 1999).
CSFV can cause severe disease in pigs, characterized by high
morbidity and mortality (van Oirschot, 1986). Infection with
highly virulent CSFV strains generally leads to death of infected
animals, whereas isolates of moderate to low virulence induce a
prolonged chronic disease (van Oirschot, 1986). Development
of infectious CSFV cDNA clones has permitted genetic
approaches for exploration of mechanisms involved with viral
replication and pathogenesis. Infectious clones (IC) of attenu-
ated and pathogenic strains have been constructed and used to
identify viral proteins or protein domains functioning in viral
replication and virulence, and to engineer live-attenuated CSF
marker vaccines (Mayer et al., 2004; Meyers et al., 1999;
Moormann et al., 1996; Moser et al., 2001; Risatti et al., 2005a,
2005b, 2006, 2007; Ruggli et al., 1996; Tratschin et al., 1998;
van Gennip et al., 2000, 2002; Widjojoatmodjo et al., 2000).
Erns has been shown to function in viral virulence. Depending
on the extent of the engineeredmutation, specific Alfort/187 Erns
mutants exhibited different degrees of attenuation when in-
oculated in swine, indicating a role for Erns in viral pathogenesis
(Meyers et al., 1999). Npro also has been shown to be involved in
virulence (Mayer et al., 2004). The deletion of Npro in the Alfort/
187 and Eystrup strains abrogates their virulence for swine.
Recently, it has been demonstrated that E1 plays a role in CSFV
virulence. A 19-nucleotide insertion in the carboxyl-end of the
E1 gene resulted in complete attenuation of the highly virulent
strain Brescia (Risatti et al., 2005b).
E2, the most immunogenic of the CSFV glycoproteins, in-
duces a protective immune response in swine (Hulst et al., 1993;
Konig et al., 1995; van Zijl et al., 1991). E2 is an essential protein
for CSFV since virus mutants containing partial or complete
deletions of the E2 gene were nonviable (van Gennip et al.,
2002). E2 has been implicated, along with Erns and E1, in viral
adsorption to the cell (Hulst and Moormann, 1997; Wang et al.,
2004). Additionally, experiments using chimeric viruses contain-
ing partial or complete replacement of the E2 gene by homo-
logous genomic regions of other pestiviruses exhibited changes
in their infectivity efficacy and/or cell tropism consistent with that
of the donor virus (Liang et al., 2003; van Gennip et al., 2000).
Previously, we have shown that chimeric virus 319.1v
(Risatti et al., 2005a) containing the E2 glycoprotein of vaccine
strain CS in the genetic background of highly virulent strain
Brescia (BICv) was completely attenuated in pigs. Here we have
mapped amino acid residues responsible for mediating that
attenuation. A series of mutant viruses were constructed based
on the genetic background of BICv and tested for their virulence
in swine. Individual or groups of amino acids were substituted in
BICv E2 glycoprotein, between amino acid positions 691 and
1064 of CSFV polyprotein, to residues located at similar
positions in vaccine strain CS. Results indicate that attenuation
of chimeric virus 319.1v requires the presence of at least 12-
amino-acid substitutions located near the carboxyl terminus of
E2 glycoprotein, between residues 882 and 1032 of the CSFV
polyprotein. Additionally, attenuated viruses induced solid pro-
tection against challenge with virulent CSFV at 3 and 28 days
post-infection.Results
The carboxyl terminal region of CS E2 glycoprotein in chimera
319.1v is responsible for viral attenuation
Chimeric virus 319.1v, containing the E2 glycoprotein of
vaccine strain CS within the genetic background of the highly
virulent strain Brescia (BICv), was markedly attenuated in pigs,
exhibiting significantly decreased virus replication during
infection and decreased virus shedding (Risatti et al., 2005a).
To further define the amino acid residues mediating attenuation,
two chimeric viruses, 357v and 358v, were constructed.
Chimera 357v contains CS residues 691 to 881 of the CSFV
polyprotein, while chimera 358v contains CS residues 882 to
1064; within the genetic background of virulent BICv (Fig. 1A).
Growth kinetics of 357v, 358v and BICv were compared in a
multistep growth curve. Primary porcine macrophage cell
cultures were infected at a multiplicity of infection (MOI) of
0.1 TCID50 per cell. Virus was adsorbed for 1 h (time 0) and
samples were collected at different time points after infection.
Replication kinetics of 357v and 358v were comparable to
parental virus BICv (Fig. 2A). However, 358v showed an
impaired capability to spread in SK6 cells, similar to the CSICv
plaque phenotype. 358v plaque size was significantly reduced
when compared to chimera 357v and parental BICv plaque
phenotypes (Fig. 6A). Accordingly, parental virus 319 also
presented with a reduced plaque size (Risatti et al., 2005a).
Virulence phenotype of 357v and 358v was assessed in
swine. Groups of 4 pigs were intranasally inoculated with 105
TCID50 of each virus. Notably, the 358v-infected group
survived infection, remaining clinically normal throughout the
observation period, whereas the 357v-infected group showed
clinical signs of disease compatible to those observed for BICv
(Risatti et al., 2005a)-infected animals (Table 1). White blood
cell (WBC), lymphocyte and platelet counts dropped drastically
by 6 DPI in 357v-infected animals, and remained low until
death, while similar counts dropped transiently in 358v-infected
animals (Fig. 3). Viremia in 358v-infected animals was transient
(6 DPI) and significantly reduced by 104 to 105 log10 from titers
observed for 357v-infected animals (Fig. 3D). A similar pattern
was observed for nasal swab and tonsil scraping samples (Fig.
3E and F). Thus, the carboxyl terminal region of CS E2
glycoprotein (358v) encompassing 182 amino acids and
differing from BICv in 13 residues (Fig. 1B) is responsible
for complete attenuation of CSFV strain Brescia.
Multiple E2 amino acid residues are associated with
358v-attenuated phenotype
Comparative sequence analysis of Brescia and CS E2
between CSFV polyprotein residues 882 and 1064 reveals no
deletions or insertions and 7% amino acids divergence including
7 non-conserved substitutions (T886M, P889L, S927L, D958G,
A975E, R979S, and L1059P), 3 semi-conserved substitutions
(T928A, H955R, and A988T) and 3 conserved substitutions
(Q892R, R994K, and I1032V). The role of these non-conserved
and semi-conserved amino acid substitutions in BICv attenua-
Fig. 1. Construction of CSFV chimeric viruses. (A) cDNA for viruses 357 and 358. (B) cDNA for chimeric viruses 886/9, 927/8, 955/8, 975, 979, 988, 1059, 31, 32,
33, 39, 40, 42 and 43. Corresponding nucleotide numbers are depicted. Substituted amino acid residues in the carboxyl terminus of E2 between Brescia and CS strains
are depicted.
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viruses containing single or double non-conserved or semi-
conserved substitutions (Fig. 1B), were comparable to chimera
358v in multistep growth curves in primary porcine macrophage
cell cultures (Fig. 2B). In vivo, groups of pigs (n=2) were
intranasally inoculated with 105 TCID50 of each of these seven
mutant viruses (Fig. 1B). All seven viruses induced disease in
swine indistinguishable from that induced by Brescia virus, with
animals dying by 11 DPI (Table 1). WBC, lymphocyte and
platelets counts dropped drastically by 6 DPI in all infected
animals, and remained low until death (Fig. 4). Virus titers in
blood, nasal swabs and tonsil scraping samples were high
(Fig. 5), resembling those observed with BICv- or 357v-infected
animals.
Mapping amino acid residues inducing attenuation in 358v
To further define relevant E2 residues inducing attenuation
of 358v. Three additional chimeric viruses (31v, 32v, 33v) were
constructed by introducing all 13 CS E2 substitutions groupedin three partially overlapping regions: 31v (T886M, P889L,
Q892R, S927L, T928A, H955R, and D958G), 32v (A975E,
R979S, A988T, R994K, I1032V, and L1059P) and 33v
(H955R, D958G, A975E, R979S, A988T, and R994K) (Fig.
1B) into BICv. Replication kinetics and virus yields for 31v,
32v, 33v, and 358v in primary swine macrophage cultures were
similar (Fig. 2C). Interestingly, 31v-infected swine presented a
delayed onset of lethal disease (Table 1), unlike swine infected
with 32v and 33v that manifested a disease pattern similar to
357v. This indicates that 7-amino-acid substitutions in 31v
(T886M, P889L, Q892R, S927L, T928A, H955R, and D958G),
located between CSFV polyprotein residues 886 and 958, while
not sufficient to completely attenuate BICv significantly
affected disease course. Despite the observed delayed pheno-
type, a drastic drop in blood cells counts was observed for all
groups from days 4 to 6 DPI, remaining low until death (Fig. 4),
with high virus titers in blood, nasal, and tonsil scraping
samples in all infected animals until death (Fig. 5).
Determination of CS amino acid residues required to
attenuate BICv was accomplished by constructing 4 additional
Fig. 2. Growth characteristics of chimeric viruses on swine macrophage cell
cultures. (A) CSFV BICv, CSICv and chimeras 357v and 358v. (B) Chimeric
viruses 886/9, 927/8, 955/8, 975, 979, 988 and 1059. (C) Chimeric viruses 31,
32, 33, 39, 40, 42 and 43. Primary swine macrophage cell cultures were infected
(MOI of 0.1). At times post infection, samples were collected and titrated on
SK6 cells for virus yield. Data are means and standard deviation of three
independent experiments.
Table 1
Swine survival, and fever response following infection with CSF chimeric
viruses
Virus Number of
survivors/total a
Mean time
to death,
days (±SD)
Fever
Days to
onset
(±SD)
Duration,
no. of days
(±SD)
Max
temperature,
°F (±SD)
357v 0/4 11.2 (1.5) 6.25 (0.5) 6.5 (1.5) 105.2 (1.4)
358v 4/4 – – – 103.1 (0.7)
886/9v 0/2 11 (0) 3.5 (0.7) 6.5 (0.7) 106.4 (0.1)
927/8v 0/2 11.5 (0.7) 3 (0) 6 (1.4) 105.3 (0.4)
955/8v 0/2 11.5 (0.7) 3.5 (0.7) 7.5 (0.7) 105.8 (0.2)
975v 0/2 11 (4.2) 3 (0) 7 (2.8) 107.4 (0)
979v 0/2 11.5 (0.7) 3 (0) 7 (1.4) 106.4 (0.4)
988v 0/2 9 (1.4) 4 (0) 4 (1.4) 106.6 (0)
1059v 0/2 11 (0) 4 (0) 5.5 (1.2) 105.7 (0.9)
31v 0/2 16 (1.4) 5 (0) 8.5 (3.5) 106.9 (0.7)
32v 0/2 8.5 (0.7) 4.5 (0.7) 5.5 (0.7) 105.6 (0.2)
33v 0/2 9 (0) 3 (0) 7 (0) 107.7 (0.1)
39v 0/2 14 (1.4) 5.5 (0.7) 5.5 (0.7) 106.5 (0.2)
40v 2/2 – 8.5 (4.9) 10 (7) 105.9 (1.5)
42v 2/2 – 7 b (0) 2 (0) 103.6 (2.2)
43v 2/2 – 5 b (0) 2 (0) 103.7 (0.4)
a Animals were infected intranasally with 105 TCID50 of each virus.
b Only one animal presented fever.
374 G.R. Risatti et al. / Virology 364 (2007) 371–382chimeric viruses (39v, 40v, 42v, and 43v). Six-amino-acid
substitutions (A975E, R979S, A988T, R994K, I1032V, and
L1059P) were progressively introduced into 31v (Fig. 1B): 39v
(T886M, P889L, Q892R, S927L, T928A, H955R, D958G,
A975E, R979S), 40v (T886M, P889L, Q892R, S927L, T928A,
H955R, D958G, A975E, R979S, A988T), 42v (T886M, P889L,
Q892R, S927L, T928A, H955R, D958G, A975E, R979S,A988T, R994K, I1032V), and 43v (T886M, P889L, Q892R,
S927L, T928A, H955R, D958G, A975E, R979S, A988T,
R994K, I1032V, L1059P). Replication kinetics and final virus
yields of 39v, 40v, 42v, and 43v, in primary swine macrophage
cell cultures, were similar to attenuated chimera 358v (Fig. 2C).
In vivo, a pattern of progressive attenuation of BICv was
observed with these mutants, extending from delayed onset of
lethal disease in 39v-infected pigs, mild disease induced by 40v,
with animals surviving infection, to complete attenuation
observed in animals infected with 42v and 43v. Blood cell
counts dropped by 6 DPI in 39v and 40v-infected animals,
remaining low until death (39v) or the end of the experimental
period (40v), while in swine infected with 42v, and 43v counts
dropped by 6 DPI, but recovered to normal levels toward the
end of the observation period (Fig. 4). Viremia and virus
shedding in 39v- and 40v-infected swine resembled that
observed for the virulent chimera 357v. Virus titers in blood
and the oronasal cavity of 42v- and 43v-infected swine
resembled those observed for the attenuated chimera 358v
(Fig. 5).
Our data indicate that virulence attenuation observed with
chimera 358v is mediated by 12 substitutions (T886M, P889L,
Q892R, S927L, T928A, H955R, D958G, A975E, R979S,
A988T, R994K, and I1032V), including 6 non-conserved
substitutions and a conserved one (I1032V) near the E2
carboxyl-terminal transmembrane domain.
Comparative analysis in the secondary structure of BICv and
358.1v
The prediction shows that the secondary structure of BICv E2
glycoprotein is composed of a random coil (∼51%), an extended
strand (∼32%), and an alpha helix (∼15%). The rest of the
Fig. 3. Peripheral blood cell counts (A–C) and virus titers (D–F) in pigs infected with chimeric viruses 357 and 358: (A) peripheral white blood cells (WBC), (B)
lymphocytes (Lymph) and (C) platelets (PLT). Counts were determined as described in Materials and methods. Virus titers of (D) nasal swabs, (E) tonsil scrapings and
(F) blood, from pigs infected with chimeric viruses 357 and 358. Each point represents the mean and standard deviation of 4 animals.
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sequence. The thirteen-amino-acid substitutions in chimera
358v between CSFV residues 882 and 1064, reduced 14 amino
acid residues in the alpha helix and increased 13 amino acids in
the extended strand, compared to BICv (Fig. 7). The differences
in the distribution of the E2 alpha helix and extended strand
between the BICv and 358v viruses are mainly located in theregion after CSFVamino acid positions 889 to 895 when adding
the extended strand, and positions 986 to 991 when disrupting
the alpha helix region (Fig. 7). Comparing the less virulent 39v
and partially attenuated 40v, it could be hypothesized that viral
attenuation would require addition and disruption, ultimately
leading to alteration of the secondary structures within this
particular area of E2. Based on that prediction, amino acid
Fig. 4. Cell counts of peripheral white blood cells (WBC), lymphocytes (Lymph) and platelets (PLT) in pigs infected with chimeric viruses 886/9, 927/8, 955/8, 975,
979, 988 and 1059 (panels on the left) or 31, 32, 33, 39, 40, 42 and 43 (panels on the right). Counts were determined as described in Materials and methods. Each point
represents the mean and standard deviation of at least two animals.
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secondary structure similar to viruses CS and 358, which
contain the 13-amino-acid substitutions in the area between
CSFV residues 882 and 1064, compared with BICv. To test
this hypothesis, a recombinant BICv containing substitutions
P889L and A988T (called 45v) was generated and its viru-
lence tested in swine. Results demonstrated that animals
infected with 45v presented a clinical disease and virus repli-
cation profiles indistinguishable from that produced by infec-
tion with BICv (data not shown). These results indicate that
attenuation of 358v could be explained by those substitutionscausing alterations of the secondary structure of the BICv E2
protein in the area between CSFV residues 882 and 1064.
Attenuated 358v induces protection against challenge with
virulent CSFV Brescia strain
The attenuate chimera 358v showed a limited ability to
spread during the infection in swine, making itself a candidate
experimental vaccine strain. Therefore, the ability of 358v to
induce a protective immune response against challenge with
virulent BICv was evaluated in swine at 3 and 28 DPI. Mock-
Fig. 5. Virus titers of nasal swabs, tonsil scrapings and blood, from pigs infected with chimeric viruses 886/9, 927/8, 955/8, 975, 979, 988 and 1059 (panels on the left)
or 31, 32, 33, 39, 40, 42 and 43 (panels on the right). Each point represents the mean and standard deviation of at least two animals.
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depression, and fever by 4 days post-challenge (DPC), with a
marked reduction of circulating leukocytes and platelets by
7 DPC (data not shown), and died or were euthanized in
extremis by 12 DPC (Table 2). Notably, 358v-vaccinated pigs
challenged at 3 DPI showed complete protection against BICv-
induced clinical disease. All pigs survived infection and
remained clinically normal, with only two animals presenting
a transient fever at 4 DPC (Table 2) and without significantchanges in their hematological values (data not shown).
Similarly, pigs challenged at 28 days post 358v vaccination
remained clinically normal (Table 2). Viremia and virus
shedding (nasal swabs, and tonsil scrapes) of BICv challenge
virus was examined at 4, 7, 14 and 20 DPC. Mock-vaccinated
animals showed viremia by 5 DPC, with virus titers remaining
high (106 TCID50/ml by 8 DPC) until death (data not shown).
Virus shedding was detected by 4 DPC reaching titers of 104–
105 TCID50/ml by 8 DPC (data not shown). In contrast, virus
Table 2
Swine survival and fever response in 358v-infected animals following challenge with BICv
Time of challenge Number of
survivors/total
Mean time
to death,
days (±SD)
Fever
Days to
onset (±SD)
Duration,
no. of days
(±SD)
Max temperature,
°F (±SD)
3 3/3 – 4.5 a (0.7) 2.2 (3.2) 103.8 (0.4)
28 3/3 – – – 102.5 (0.9)
Mock 0/3 12 (2) 4 (0) 7 (0) 107.5 (0.1)
a Two of three animals presented with fever.
378 G.R. Risatti et al. / Virology 364 (2007) 371–382titers were below the level of detection in blood, nasal, and
tonsil samples obtained from all pigs vaccinated with attenuated
chimera 358v (data not shown).
Unlike most of the virulent CSFV strains, CS vaccine strain
does not react with E2-specific mAb WH308 (Edwards et al.,
1991) (Data not shown). Therefore, reactivity with mAbWH308
can potentially be used as a viral antigenic marker. Chimeras
357v and 358v were analyzed for the ability to react with mAb
WH308. SK6 cells infected with chimera 357v strongly react
with mAb WH308, while cells infected with chimera 358v lack
reactivity with themonoclonal antibody (Fig. 6B). This indicates
that the mAbWH308 epitope resides in an area between residues
882 and 1064 of the CSFV polyprotein (Fig. 1B). Further
mapping of the epitope was assessed by analyzing the reactivity
of 31v, 32v, and 33v against mAbWH308 in SK6-infected cells.
31v lack of reactivity indicates that the epitope is located
between residues 882 and 958 of the CSFV polyprotein (Fig.
6C). Among the three double mutants within this area, 886/9v,
927/8v and 955/8v used in these studies, only mutant 886/9v did
not react with mAbWH308. This lack of reactivity indicates thatFig. 6. Plaque formation of CSFV chimeric viruses on SK6 cell cultures. (A) BICv, C
viruses 357v and 358v; and (C) 31v, 32v, 33v, 358v, 886/9v, 927/8v and 955/8v. Cell cult
at 37 °C. Plates were fixed with 50% (v/v) ethanol/acetone and stained by immunohisT886 and P889 in BICv are directly involved with mAbWH308
binding.
Discussion
The genetic bases and the molecular mechanisms underlying
CSFV virulence remain unclear, with few studies associating
specific viral proteins or genomic regions with virulence. Single
or double codonmutation of Erns that inhibited its RNase activity
resulted in attenuation of the CSFV Alfort/Tübingen strain in
swine (Meyers et al., 1999) and, similarly, mutation of the Erns
RNase domain of BVDVattenuated the virus in cattle (Meyer et
al., 2002). Complete deletion of Npro from virulent CSFV strains
Alfort/187 and Eystrup attenuated these viruses in swine (Mayer
et al., 2004), as did an in-frame insertion of 19 amino acids into
the E1 gene of CSFV strain Brescia (Risatti et al., 2005b).
Recently, E2 of the CSFV Brescia strain has been shown to
harbor determinants associated with virulence. Mutations, either
abrogating glycosylation of the amino acid at position 805 or
replacing amino acid residues 829 to 837 with the homologousSICv, 357v and 358v. (B) Reactivity with mAb WH303 and WH308 of chimeric
ureswere infectedwith 50–100TCID50, overlaidwith 0.5%agarose, and incubated
tochemistry with the corresponding mAb as described in Materials and methods.
Fig. 7. The predicted secondary structures of 358.1v and BICv E2 proteins. Numbers represent amino acid residues in the CSFV polyprotein. The purple, red, and blue
vertical lines indicate amino acid residues with random coil, extended strand, and alpha helix structures, respectively. The arrows indicate the mutations at amino acid
positions 889 (P→L), 988 (A→T), and 1059 (L→P) associated with three most significant structural differences between the two strains. The dash indicates the
transmembrane domain.
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attenuation of the highly virulent parental strain (Risatti et al.,
2006, 2007). Additionally, it has been reported that changes at
residue 710 in E2, in combination with point mutations in Erns,
induced a reduced virulence of CSFV strain Brescia (Van
Gennip et al., 2004).
In a previous report, we have shown that replacement of the
E2 gene in CSFV strain Brescia with that of vaccine strain CS
resulted in a chimeric virus, 319.1v, that was significantly
attenuated in vivo, demonstrating considerably decreased virus
replication in tonsils, a transient viremia, a limited general-
ization of infection, and decreased virus shedding (Risatti et al.,
2005a). Here we have demonstrated that attenuation of chimeric
virus 319.1v is due to the presence of a stretch of 12-amino-acid
substitutions lying within the carboxyl terminus of the E2
glycoprotein, between residues 882 and 1032 of the CSFV
polyprotein. This represents a third area within the E2 gene
associated with virulence; two other independent determinants
are located in a glycosylation site at position 805 and the other
in a region between amino acid residues 805 and 837 of the
CSFV Brescia polyprotein (Risatti et al., 2006, 2007).
Chimeric virus 358v, which contains the genetic background
of virulent BICv and 182 residues encompassing the carboxyl
terminal half of CS E2 (Fig. 1A) was attenuated in swine. The
amino acid sequence in this portion of the E2 gene differs in 13
amino acids between attenuated CS and virulent BICv. Only
when 12 of the 13 residues were substituted from BICv to CS
sequence (42v) attenuation was observed.
Interestingly, none of the 12 substitutions, tested as a single-
or double-amino-acid mutation, affected BICv virulent pheno-
type. Even double mutant P889L/A988T (45v) containing the
only two substitutions predicted to significantly alter the
secondary structure of the area between amino acid residues
882 and 1032 was unable to revert the virulent phenotype. These
observations suggested that a larger number of residues were
necessary to impart an attenuated phenotype. Moreover, viruses
31v, 32v and 33v, where stretches of up to six residues were
substituted from BICv to CS amino acids (Fig. 1B), were still
unable to induce a completely attenuated phenotype in pigs.
Thus, viruses 39v, 40v, 42v, and 43v (Fig. 1B) were constructed
by progressively introducing 2, 3, 5, and 6 BICv to CS amino
acid substitutions, respectively, into the genetic background of
31v. This approach resulted in the production of viruses that
showed progressive degrees of attenuation from a virulentphenotype, with no surviving animals, to 39v, with a transient
fever in animals inoculated with 42v and 43v (Table 1).
Themechanismsmediating this attenuation remain unknown.
It could be hypothesized that attenuating substitutions in BICv
E2 glycoprotein conceivably involve aspects of virus attachment
and/or efficient entry into critical target cells in vivo. Also
suggestive of a role for E2 mutations in virus attachment and/or
entry was the small plaque phenotype exhibited by 358v, in
accordance with the same phenotype showed by the vaccine
strain CSICv. Although an association between in vitro plaque
size reduction and in vivo attenuation of CSFV has yet to be
firmly established, certain observations suggest a relationship
(Risatti et al., 2005a, 2005b, 2006, 2007).
Finally, we observed that chimera 358v, despite having a
limited replication in vivo, characterized by reduced viremia,
generalization of infection, and virus shedding, induced a rapid
and effective protective response against virulent BICv. Similar
protection patterns have been described previously (Biront et al.,
1987; Terpstra and Wensvoort, 1988) for live-attenuated vaccine
(LAV) strains of CSFV. This rapid, antibody-independent
protection likely involves mechanisms of innate immunity (e.g.
macrophages/monocytes, dendritic cells, and NK cells, and their
products). Additionally, the lack of reactivity of 358v to mAb
WH308,which recognizes a highly specific CSFVepitope,makes
this virus a potential live-attenuated marker vaccine candidate.
In summary, a novel CSFV genetic virulence determinant
associated with the E2 glycoprotein has been identified.
Although the mechanism underlying the attenuation remains
unknown, improving the understanding of the genetic basis of
CSFV virulence will permit future rational design of live-
attenuated CSF vaccines of enhanced safety, efficacy and utility.
Materials and methods
Viruses and cells
Swine kidney cells (SK6) (Terpstra et al., 1990), free of
Bovine Viral Diarrhea Virus (BVDV) were used throughout this
study. SK6 cells were cultured in Dulbecco's minimal essential
medium (DMEM) (Gibco, Grand Island, NY) with 10% fetal
calf serum (FCS) (Atlas Biologicals, Fort Collins, CO). CSFV
Brescia strain (obtained from the Animal and Plant Health
Inspection Service, Plum Island Animal Disease Center) was
propagated in SK6 cells and used for the construction of an
380 G.R. Risatti et al. / Virology 364 (2007) 371–382infectious cDNA clone (Risatti et al., 2005a). Titration of CSFV
in clinical samples was performed in 96 well plates (Costar,
Cambridge, MA) using SK6 cells. After 4 days in culture, viral
infectivity was detected by immunoperoxidase assay using the
CSFV monoclonal antibody WH303 (Edwards et al., 1991) and
the Vectastain ABC kit (Vector Laboratories, Burlingame, CA)
(Risatti et al., 2003). Titers were calculated using the method of
Reed and Muench (1938) and expressed as TCID50/ml. As
performed, test sensitivity was >1.97 log10 TCID50/ml.
Primary swine macrophage cell cultures were prepared as
described by Zsak et al. (1996).
Construction of CSFV Brescia/CS chimeric cDNA infectious
clones (IC)
Two chimeric viruses, designated 357v and 358v, were
constructed containing the amino (CSFV residues 691–881) and
the carboxyl (CSFV residues 882–1064) regions of the CS E2
glycoprotein in the context of the Brescia (BICv) strain,
respectively (Fig. 1). Construction of these chimeric viruses
was accomplished through the generation of several intermedi-
ate plasmids. First, the CSFV genomic region containing the E2,
p7, and NS23 genes from strains Brescia and CS was PCR
amplified using the CSFV-specific primers F2379 and R6636
(Table 3) to include the native restriction endonuclease sites
NaeI (position 2438) and BamHI (position 6435). The amplified
products were then cloned into a pCR4Topo vector, using the
TOPO TA Cloning® kit (Invitrogen, Carlsbad, CA) to create the
plasmids pBreN/B and pCSN/B. Next, a unique SacII restriction
enzyme site (Table 3) was introduced into both plasmids at the 3′
end of the E2 gene (position 3540) by site-directed mutagenesis
using the QuikChange® XL Site-Directed Mutagenesis kit
(Stratagene, La Jolla, CA) to generate the plasmids pBreN/
BSacII and pCSN/BSacII. These plasmids were then digested
with SacII/BamHI and NaeI/SacII, independently. The SacII/
BamHI fragment and NaeI/SacII fragment from pCSN/BSacII
were then introduced into the SacII/BamHI-digested pBreN/
BSacII and the NaeI/SacII-digested pBreN/BSacII to yield the
plasmids pN(Bre)S/B(CS) and pN(CS)S/B(Bre), respectively. A
second unique restriction enzyme site,AgeI, was then introduced
by site-directed mutagenesis into both of these plasmids atTable 3
Oligonucleotides used for construction of the chimeric infectious clones
Primer Sequence
F2379 5′ CCTCATCTGCTTGATAAAAG 3′
R6636 5′ CCTTCTCTGGGCTTGTTC 3′
FSacII 5′ GAACAACTCGCCGCGGGTCTACAGTTAGG
FAgeI 5′ ATGTGTGAAAGGTGAACCGGTGACCTACA
F886/9 5′ CCAGTGACCTACATGGGGGGGCTAGTAAA
F927/8 5′ GGTTACAGAATAGTGGATTTAGCGGACTGT
F955/8 5′ CACAACTGTCAAGGTGCGTGCATTAGGCG
F975 5′ GATCGCTTCTAGTGAGGGACCTGTAAGG3′
F979 5′ TAGTGCGGGACCTGTAAGTAAAACTTCCTG
F988 5′ CTTCCTGTACATTCAACTACACAAAAACTC
F1059 5′ GTTCTAACAGAACCCGCCGCGGGTCTACA
Bold characters indicated mutations. When not showed, reverse primers are compleposition 3004, located approximately in the middle of the E2
gene, to generate the plasmids pN(Bre)S/B(CS)AgeI and pN
(CS)S/B(Bre)AgeI (Table 3). These plasmids were indepen-
dently digested with restriction enzymes NaeI/AgeI and AgeI/
SacII. The NaeI/AgeI fragment and AgeI/SacII fragment from
pN(Bre)S/B(CS)AgeI were cloned into pN(CS)S/B(Bre) to
obtain the plasmids pN/BBre5′E2CS and pN/BBre3′E2CS,
respectively. In a final step, theNaeI/BamHI fragments from pN/
BBre5′E2CS and pN/BBre3′E2CS were independently cloned
into pBIC to obtain the full-length plasmids pB(5′E2)CS (357)
and pB(3′E2)CS (358), respectively (Fig. 1A).
Seven mutant full-length clones containing double- or
single-amino-acid substitutions in the E2 gene area between
CSFV polyprotein residues 886 and 1059 were generated by
PCR-based site-directed mutagenesis of full-length cDNA clone
pBIC as described above. Full-length mutant clones were named
p886/9, p927/8, p955/8, p975, p979, p988 and p1059 (Fig. 1B).
The mutagenic oligonucleotide primer sets (Table 3) were
designed following manufacturer's instructions (Stratagene).
Chimeric full-length clones, p31, p32 and p33, contain all
CS amino acids in the region between residues 882 and 958
(p31), between 955 and 994 (p33) and between 975 and 1064
(p32) of the CSFV BICv polyprotein (Fig. 1B). Chimeras were
generated by progressively introducing mutations by PCR-
based site-directed mutagenesis of full-length cDNA clone
pBIC, as described above. Full-length cDNA chimera p31 was
obtained using p886/9 as a DNA template and subsequently
substituting residues 892, 927/8 and 955/8 for CS residues (Fig.
1B). Full-length cDNA chimera p32 was obtained using p975 as
a DNA template and subsequently substituting residues 979,
988, 994, 1032 and 1059 for CS residues. Full-length cDNA
chimera p33 was obtained using p955/8 as a DNA template and
subsequently substituting residues 975, 979, 988 and 994 for CS
residues (Fig. 1B).
Chimeric full-length cDNA clones p39, p40, p42 and p43 are
derived from p31 and they were obtained by progressively
substituting BICv residues with CS E2 residues between amino
acid positions 882 and 979 (p39), between 882 and 988 (p40),
between 882 and 1032 (p42), and between 882 and 1064 (p43)
of the CSFV polyprotein (Fig. 1B). Full-length chimera p39 was
obtained using plasmid p31 as DNA template and subsequentlyFunction
PCR pBreN/B and pCSN/B
3′ Insert SacII site
CGGGGGG 3′ Insert AgeI site
ACAATGC 3′ Mutate residues 886/9
AACAGAGATGGC 3′ Mutate residues 927/8
AAAGACTAGGCCCT 3′ Mutate residues 955/8
Mutate residue 975
TACATTC 3′ Mutate residue 979
TGAGGAACAGG 3′ Mutate residue 988
G 3′ Mutate residue 1059
mentary to the forward primers. Enzymatic restriction sites are underlined.
381G.R. Risatti et al. / Virology 364 (2007) 371–382substituting residues 975 and 979 for CS residues. p40 full-
length cDNA was obtained after introducing CS residue 988
into plasmid p39. p42 full-length cDNA was obtained after
introducing CS residues 994 and 1032 into plasmid p40, and
p43 full-length cDNAwas generated by introducing CS residue
1059 into plasmid p42.
Rescue of CSFV chimeric viruses
Full-length genomic clones were linearized with SrfI and in
vitro transcribed using the T7 MEGAscript® system (Ambion,
Austin, TX) RNA was precipitated with LiCl. The RNA was
then transfected into SK6 cells by electroporation at 500 V,
720 Ω, 100 W with a BTX 630 electroporator (BTX, San
Diego, CA). Cells were plated in 12-well plates and 25-cm2
flasks, and incubated for 4 days at 37 °C and 5% CO2. Virus was
detected by immunoperoxidase staining using a CSFV E2-
specific monoclonal antibody, WH303 (Edwards et al., 1991).
Stocks of rescued viruses were stored at −70 °C.
DNA sequencing
Full-length clones and in vitro rescued viruses were
completely sequenced with CSFV-specific primers by the
dideoxynucleotide chain-termination method (Sanger et al.,
1977). Sequencing reactions were prepared with the Dye
Terminator Cycle Sequencing Kit (Perkin-Elmer, Boston,
MA). Reaction products were sequenced on an ABI-PRISM
3700 automated DNA Sequencer (PE Biosystems, Foster
City, CA). Sequence data was assembled with the Phrap
software program, with confirmatory assemblies performed
using CAP3 (Huang and Madan, 1999). The final DNA
consensus sequence represented, on average, fivefold redun-
dancy at each base position.
Animal infections
To assess virulence of all chimeric viruses, 40-lb pigs aged 10
to 12 weeks old were randomly allocated into groups of two
animals each. Pigs were intranasally inoculated with 105 TCID50
of BICv, or one of the chimeric viruses. Clinical signs (anorexia,
depression, fever, purple skin discoloration, staggering gait,
diarrhea and cough) were observed daily throughout the
experiment.
For protection studies, 9 pigs were randomly allocated into 3
groups of 3 animals each. Pigs in groups 1 and 2 were inoculated
with 358v, and animals in group 3 were mock-infected. At 3
(group 1) or 28 DPI (group 2), animals were intranasally
challenged with 105 TCID50 of BICv, along with animals in
group 3. Blood, serum, nasal swabs and tonsil scrapings were
collected at designated times after challenge. Clinical signs and
body temperature were recorded daily throughout the experi-
ment as described above.
Total and differential white blood cells counts
Blood was obtained from the anterior vena cava in EDTA-
containing tubes (Vacutainer). Total white blood cell, lympho-cyte and platelet counts were obtained using a Beckman Coulter
ACT (Beckman, Coulter, CA).
Protein sequence analysis
Protein secondary structure of E2 wild-type and mutants was
predicted using a consensus method described by Combet et al.
(2000). Functional domains of the protein were also predicted
with SMART (Letunic et al., 2006), PSI-BLAST (Altschul et al.,
1997), and Interpro (Mulder et al., 2005).
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